NICE Announces Second Strike Against Gilenya For Cost-Effectiveness
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE says that additional information provided by Novartis does not satisify its requirement for proof of cost-effectiveness of Gilenya.